Skip to content

Medical Racism Reference

Medical racism was the operation of racism through health-care access, assessment, treatment, technology, research, education, policy, and institutional practice. It included explicit racial prejudice but did not depend on one clinician’s intent. A rule, algorithm, device, referral system, or ordinary clinical habit could reproduce racial inequity even when no participant used openly racist language.

Anti-Black racism was a central and extensively documented part of United States medical history. Other racialized communities also encountered distinct forms of exclusion, stereotyping, language discrimination, unequal access, and medical harm. Those histories overlapped but were not interchangeable.

Definition and Scope

Medical racism included interpersonal conduct, such as treating one patient’s pain report as less credible, and structural conduct, such as distributing specialists, insurance access, research investment, or high-quality facilities unequally. It also included clinical tools that treated broad racial categories as biological facts when the actual relevant variables were ancestry, genetics, environment, exposure, socioeconomic conditions, or the effects of racism itself.

A racial disparity documented an unequal pattern; it did not by itself identify every mechanism behind that pattern or prove the motive in one encounter. Evidence of medical racism came from the convergence of outcome data, treatment and access data, controlled studies, chart review, institutional policy, patient reports, historical records, and investigation of specific clinical tools.

Race-conscious care and race-based medicine were different. Race-conscious care recognized that racism, segregation, unequal exposure, and barriers to care could shape health and treatment. Race-based medicine used race as though it were a stable biological property or a precise substitute for an individual measurement. Clinically relevant genetic ancestry, organ function, skin pigmentation, medication response, and environmental exposure required direct assessment whenever possible.

Evidence and Measurement

The National Academies’ 2024 report ‘’Ending Unequal Treatment’’ concluded that the United States had made little progress toward health-care equity since the 2003 ‘’Unequal Treatment’’ report and that racial and ethnic inequity remained a fundamental flaw in the health-care system. The report identified interacting drivers at interpersonal, institutional, technological, geographic, policy, insurance, workforce, and societal levels.

Pain research documented one clinical pathway. A 2016 study of white lay participants and white medical students and residents found that endorsement of false beliefs about biological differences between Black and white people was associated with lower pain ratings for Black patients and less accurate treatment recommendations. The study did not establish that every clinician held those beliefs; it demonstrated that explicitly false biological ideas remained present within a measured training sample and could affect judgment.

Maternal mortality provided a population-level outcome measure rather than proof of one cause in every death. In United States vital-statistics data for 2023, the maternal mortality rate for non-Hispanic Black women was 50.3 deaths per 100,000 live births, compared with 14.5 for non-Hispanic white women, 12.4 for Hispanic women, and 10.7 for non-Hispanic Asian women. The National Center for Health Statistics cautioned that maternal-death counts were relatively small and that reporting accuracy continued to be evaluated.

Clinical technology also carried measurable inequity. The United States Food and Drug Administration found evidence that prescription pulse oximeters could perform differently in people with dark skin pigmentation and that this disparity could increase risk. Professional bodies later moved away from race coefficients in kidney-function estimates and pulmonary-function interpretation because broad racial categories were not defensible biological measurements and could alter access to diagnosis or treatment.

Historical and Policy Context

The USPHS Untreated Syphilis Study at Tuskegee

From 1932 to 1972, the United States Public Health Service conducted a study of untreated syphilis with the Tuskegee Institute. The study enrolled 600 Black men, including 399 with syphilis and 201 without it. Informed consent was not obtained, participants were told they were being treated for “bad blood,” and penicillin was not offered after it became the treatment of choice. An advisory panel declared the study ethically unjustified in 1972, and it was stopped later that year.

The study became one major example of state-sponsored medical deception and racial exploitation. Distrust of health-care and research institutions could not be reduced to this event alone; it also reflected continuing personal, family, and community experience with unequal treatment.

Henrietta Lacks and HeLa Cells

In 1951, tissue obtained from Henrietta Lacks during cervical-cancer treatment at Johns Hopkins was used to establish the HeLa cell line without her knowledge or consent. The cells became foundational to biomedical research. The National Institutes of Health and members of the Lacks family created a controlled-access agreement for HeLa genome data in 2013 and reaffirmed the family’s role in 2023. The later agreement did not change the absence of consent in the original tissue collection.

Reform of Race-Based Clinical Tools

During the early twenty-first century, medical organizations increasingly reviewed algorithms and reference equations that used race. In 2021, the National Kidney Foundation and American Society of Nephrology recommended race-free equations for estimating glomerular filtration rate. In 2023, the American Thoracic Society recommended race-neutral pulmonary-function interpretation. FDA review of pulse oximetry similarly shifted performance testing toward direct measurement across a wider range of skin pigmentation rather than reliance on inadequate racial sampling.

These reforms addressed specific tools. They did not establish that racial inequity had ended elsewhere in care.

Mechanisms

Access and Continuity

Insurance design, referral requirements, transportation, facility location, workforce distribution, appointment availability, and the resources of hospitals and clinics affected who reached timely care. A nominally identical benefit could produce unequal access when specialist networks, paid leave, language services, or accessible transportation differed.

Fragmentation also increased the burden of proof. Patients and families with fewer resources were more likely to repeat histories, locate records, miss work, travel farther, or wait through multiple referrals before a clinician saw the complete pattern.

Credibility, Assessment, and Diagnosis

Racial stereotypes could shape whose symptoms were treated as urgent, whose pain was believed, and whose distress was interpreted as fear, noncompliance, aggression, intoxication, or attention-seeking. Premature attribution to anxiety, body size, behavior, or presumed poor self-management could delay evaluation of a separate medical cause.

Communication and disability could compound the problem. Speech differences, AAC use, intellectual disability, cognitive fatigue, postictal confusion, or difficulty answering quickly could be mistaken for lack of competence. A Black disabled person could be simultaneously presumed less credible, less intelligent, and more threatening. Direct communication, accessible explanations, supported decision-making, and attention to the person’s baseline were therefore both access practices and diagnostic-safety practices.

Pain and Symptom Management

Pain inequity could occur through lower pain ratings, delayed analgesia, lower doses, greater suspicion, or failure to offer the same range of nonpharmacological and specialist options. Equitable pain care did not require indiscriminate opioid prescribing. It required the same individualized assessment of severity, function, contraindications, prior response, treatment goals, and risk for every patient.

Devices, Algorithms, and Reference Standards

A clinical tool could encode inequity through its training data, calibration population, race coefficient, or failure to measure a relevant physical trait directly. Darker skin pigmentation could affect optical devices; broad racial categories could distort kidney or lung-function calculations; and an algorithm trained on unequal spending or utilization could learn past access barriers as though they represented lower medical need.

Removing race from a tool was not automatically sufficient. Replacement tools required validation across the people who would use them, transparent reporting of performance limits, and monitoring for downstream effects on diagnosis, medication, disability benefits, transplant access, or treatment eligibility.

Treatment, Follow-Up, and Institutional Response

Medical racism could shape which treatment was offered, how quickly abnormal findings were followed, whether a patient received rehabilitation or home support, and how staff responded to disagreement or distress. Once a racialized label entered the chart, later clinicians could repeat it without an independent assessment.

Weak complaint systems compounded harm when the same institution controlled care, documentation, internal investigation, and access to appeal. Accessible patient-relations processes, independent review, chart correction, and outcome data disaggregated by race and ethnicity made patterns more visible.

Consequences

Medical racism could lead to delayed diagnosis, undertreated symptoms, preventable complications, avoidable disability or death, medical debt, lost work or education, and reduced access to future care. It could also produce medical trauma, distrust, anticipatory fear, and delayed help-seeking during later illness.

Distrust was not a cultural defect to be corrected in the patient. Trustworthiness depended on transparent practice, reliable follow-up, respect for consent, accessible communication, community accountability, and evidence that institutions changed harmful behavior.

Effective and Accountable Practice

Accountable systems examined access, testing, treatment, complications, readmissions, pain management, and outcomes by disaggregated race and ethnicity while protecting privacy. They investigated gaps rather than treating race as the cause of the gap.

Clinical practice used direct measurements instead of race proxies whenever possible, validated devices and algorithms across relevant skin tones and populations, communicated uncertainty, and reassessed decisions when a person changed from baseline. Informed consent required accessible explanation of purpose, alternatives, risk, data use, tissue use, privacy, and the right to refuse.

Directly addressing patients, providing interpreters and AAC, allowing chosen supporters, and using supported decision-making reduced the combined effects of racism and communication ableism. Community partnership, paid patient expertise, independent oversight, and authority to change policy mattered more than one-time bias training alone.

Documented Incidents and Patterns

Andy Davis and Sarah Davis

Andy was a Black disabled child with spastic diplegic cerebral palsy, epilepsy, speech differences, and chronic pain. During the 1990s, clinicians repeatedly minimized his pain and treated escalating spasms as an expected part of cerebral palsy rather than offering adequate reassessment and pain management. Concern about presumed medication misuse made access to stronger symptom control more difficult.

Sarah, a registered nurse, combined clinical knowledge with detailed knowledge of Andy’s baseline. She and Marcus Davis repeatedly challenged medical and educational systems that treated Andy’s motor and speech disabilities as evidence of intellectual disability. Andy did not have an intellectual disability.

Andy’s later writing addressed medical racism, presumed incompetence, and the intersection of Blackness and disability. His work included ‘’Invisible Until Inconvenient’’ and the 2033 collection ‘’The Cost of Being Misread: Essays on Black Disabled Life’‘. His collaboration with Logan produced ‘’Two Generations, One Fight’‘, ‘’Pain, Presumption, and Power’‘, the CP Pain Protocol, ‘’From Room 118 to the Clinic’‘, and ‘’Dear Dr. Weston’‘. The protocol brought Andy’s lived knowledge of cerebral-palsy pain into clinical assessment without treating one patient’s experience as universal.

Charlie Rivera

Charlie experienced severe vomiting, motion sickness, fatigue, fainting, pain, and light sensitivity from childhood. Clinicians repeatedly treated acute consequences without investigating the larger multi-system pattern. His Puerto Rican identity, small body, high voice, emotional directness, and queer or gender-nonconforming presentation made it easier for adults to frame visible distress as exaggeration.

Reina documented the symptoms and continued seeking care. Charlie’s repeated dismissal damaged his trust in clinicians and contributed to his reluctance to return. A late-2027 hospitalization confirmed gastroparesis and, through repeat upright testing after volume and nutritional stabilization, POTS. Later evaluation established ME/CFS, hypermobile Ehlers-Danlos syndrome, and mast cell activation syndrome.

Logan Weston and Julia Weston

Before Logan’s Type 1 diabetes diagnosis, Julia documented excessive thirst, frequent urination, fatigue, and decline from his baseline. Multiple clinicians attributed the pattern to puberty, stress, or ordinary growth despite Julia’s medical training and repeated advocacy. The diagnostic delay shaped the family’s vigilance and Logan’s later understanding of how Black patients and Black parents could be dismissed even when they used clinical language and arrived prepared.

Andy Davis’s work on Black disabled youth became one of Logan’s major professional influences. Logan’s later research addressed pain disparities, diabetic neuropathy, post-trauma recovery, and medical racism. The Weston Pain and Neurorehabilitation Centers incorporated patient autonomy, accessible communication, interdisciplinary pain care, and institutional review into its clinical model.

Elliot Landry

Elliot was a mixed-race Black American and Puerto Rican man with pituitary gigantism and a large body. Throughout his life, clinicians treated weight as the default explanation for pain, fatigue, and discomfort. In the months before his oligodendroglioma diagnosis, worsening neurological symptoms were attributed to dehydration, stress, overwork, and weight while he waited for imaging to be scheduled.

The pattern combined anti-fat bias with racialized assumptions about credibility, responsibility, and whose distress merited investigation. Elliot’s reluctance to return for care was grounded in repeated experience rather than lack of concern for his health. His tumor was discovered after back-to-back seizures progressed to convulsive status epilepticus; the delayed presentation is documented in Low-Grade Glioma (Brain Tumor) and Medical Gaslighting Reference.

Connor Martinez

Main article: Connor Martinez Appendicitis and Septic Crisis (Thanksgiving 1998) - Event

On Thanksgiving 1998, sixteen-year-old Connor waited approximately three hours at Huntington Memorial Hospital despite severe lower-right abdominal pain, fever, nausea, and a rigid abdomen. The delay was an instance of anti-Latino medical racism: staff treated his pain as non-urgent, and his appendix had perforated by the time Katherine Wallace’s connections secured an examination. His mother, Rosa Martinez, understood the failure as both his parent and a registered nurse at the same hospital.

Connor survived abdominal infection and septic shock with permanent gastroparesis, months of cognitive recovery, mild residual cognitive effects, and medical PTSD. His distrust and contained anger persisted into adulthood. He supported Cassidy Harris’s healthcare-equity advocacy with explicit consent and boundaries, voted for policies addressing healthcare equity, and occasionally gave public testimony. Those contributions did not make his medical history public property or replace his identity as a partner, friend, and person with work and interests beyond the crisis.

Sources

Systemic Issues Healthcare Racism Disability and Medical References